APOE polymorphisms and cognitive functions in patients with brain tumors

Neurology

Volumn 83, Issue 4, 2014, Pages 320-327

  Correa, Denise D ^a,b   Satagopan, Jaya ^a   Baser, Raymond E ^a   Cheung, Kenneth ^a   Richards, Elizabeth ^a   Lin, Michael ^b   Karimi, Sasan ^a   Lyo, John ^a   DeAngelis, Lisa M ^a,b   Orlow, Irene ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ALLELES; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; BRAIN NEOPLASMS; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NERVE FIBERS, MYELINATED; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING;

EID: 84905828563     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000617     Document Type: Article

References (39)

1. Correa DD. Neurocognitive function in brain tumors. Curr Neurol Neurosci Rep 2010;10:232-239.
2. Behin A, Delattre JY. Neurologic sequelae of radiotherapy on the nervous system. In: Schiff D, Wen PY, editors. Cancer Neurology in Clinical Practice. Totowa, NJ: Humana Press; 2003:173-191.
3. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996;47:387-400.
4. Richard F, Amouyel P. Genetic susceptibility factors for Alzheimer's disease. Eur J Pharmacol 2001;412:1-12.
5. Jordan BD. Genetic influences on outcome following traumatic brain injury. Neurochem Res 2007;32:905-915.
6. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003;12:612-619.
7. Correa DD, DeAngelis LM, Shi W, Thaler H, Lin M, Abrey LE. Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol 2007;81:175-184.
8. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 2006;24:1305-1309.
9. Belbin O, Dunn JL, Ling Y, et al. Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer's disease. Hum Mol Genet 2007;16:2199-2208.
10. Bizarro A, Seripa D, Acciarri A, et al. The complex interaction between APOE promoter and AD: an Italian casecontrol study. Eur J Hum Genet 2009;17:938-945.
11. Valenza A, Bizarro A, Marra C, et al. The APOE-491 A/T promoter polymorphism effect on cognitive profile of Alzheimer's patients. Neurosci Lett 2010;472:199-203.
12. Xin XY, Ding JQ, Chen SD. Apolipoprotein E promoter polymorphisms and risk of Alzheimer's disease: evidence from meta-analysis. J Alzheimers Dis 2010;19:1283-1294.
13. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
14. O'Brien KM, Orlow I, Antonescu CR, et al. Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants. PLoS One 2013;8:e62119.
15. Corn BW, Yousem DM, Scott CB, et al. White matter changes are correlated significantly with radiation dose. Cancer 1994;74:2828-2835.
16. Packard CJ, Westendorp RGJ, Stott DJ, et al. Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc 2007;55:1777-1785.
17. Flory JD, Manuck SB, Ferrell RE, et al. Memory performance and the apolipoprotein E polymorphism in a community sample of middle-aged adults. Am J Med Genet 2000;96: 707-711.
18. Sabia S, Kivimaki M, Kumari M, et al. Effect of apolipoprotein E e4 on the association between health behaviors and cognitive function in late midlife. Mol Neurodegener 2010;5:23.
19. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013. Available at: http://www.Rproject. org/.
20. Relkin NR; National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996;347:1091-1095.
21. Wagle J, Farner L, Flekkov K, et al. Cognitive impairment and the role of the ApoE epsilon4-allele after stroke: a 13 months follow-up study. Int J Geriatr Psychiatry 2010;8:833-843.
22. Nilsson LG, Adolfsson R, Backman L, et al. The influence of APOE status on episodic and semantic memory: data from a population-based study. Neuropsychology 2006; 20:645-657.
23. Caselli RJ, Locke DE, Dueck AC, et al. The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimers Dement 2014;10:84-92.
24. Gibson GE, Haroutunian V, Zhang H, et al. Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol 2000;48:297-303.
25. Poirer J. Apolipoprotein E in the brain and its role in Alzheimer's disease. J Psychiatry Neurosci 1996;21:128-134.
26. Nathan BP, Bellosa S, Sanan DA, et al. Differential effects of apolipoprotein E3 and E4 on neuronal growth in vitro. Science 1994;264:850-852.
27. Ryan L, Walther K, Bendlin BB, et al. Age-related differences in white matter integrity and cognitive function are related to APOE status. Neuroimage 2011;54:1565-1577.
28. Cherbuin N, Leach LS, Christensen H, et al. Neuroimaging and APOE genotype: a systematic qualitative review. Dement Geriatr Cogn Disord 2007;24:348-362.
29. Sugihara S, Ogawa A, Nakazaro Y, et al. Cerebral B amyloid deposition in patients with malignant neoplasms: its prevalence with aging and effects of radiation therapy on vascular amyloid. Acta Neuropathol 1995;90:135-141.
30. Greene-Schloesser D, Robbins ME, Pfeifer AM, et al. Radiation-induced brain injury: a review. Front Oncol 2012;2:73.
31. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008;13:1285-1295.
32. Merchant C, Tang MX, Albert S, et al. The influence of smoking on the risk of Alzheimer's disease. Neurology 1999;52:1408-1412.
33. Reitz C, den Heijer T, van Duijn C, Hofman A, Breteler MM. Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology 2007;69:998-1005.
34. Kalapatapu RK, Delucchi KL. APOE e-4 genotype and cigarette smoking in adults with normal cognition and mild cognitive impairment: a retrospective baseline analysis of a national dataset. Am J Drug Alcohol Abuse 2013; 39:219-226.
35. Ott A, Slooter AJC, Hofman A, et al. Smoking and risk for dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840-1843.
36. van Duijn CM, Havekes LM, Van Broeckhoven C, de Knijff P, Hofman A. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. BMJ 1995;310:627-631.
37. Bangen KJ, Beiser A, Delano-Wood L, et al. APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. J Stroke Cerebrovasc Dis 2013;22:1361-1369.
38. Davies G, Harris SE, Reynolds CA, et al. A genome-wide association study implicates the APOE locus in nonpathological cognitive aging. Mol Psychiatry 2014;19:76-87.
39. Alexopoulos P, Richter-Schmidinger T, Horn M. Hippocampal volume differences between healthy young apolipoprotein E e2 and e4 carriers. J Alzheimers Dis 2011;26:207-210.